# SIGA — SIGA Technologies Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** SIGA  
**Sources:** 21  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-siga-siga-technologies-inc-catalysts-narrative-risks-10402

---

## SIGA Technologies Inc. (SIGA) — As of 2026-10-31

**Company snapshot:** SIGA Technologies, Inc. (Nasdaq: SIGA) is a commercial-stage pharmaceutical company based in New York, focused on health security and infectious-disease countermeasures, with its lead product TPOXX (tecovirimat) — an oral (and IV) antiviral for smallpox and other orthopoxviruses [[1]](https://finance.yahoo.com/healthcare/articles/siga-host-business-call-november-113000844.html), [[5]](https://tickernerd.com/stock/siga-forecast/), [[27]](https://www.siga.com/). CEO is Dr. Diem Nguyen and CFO is Daniel Luckshire [[1]](https://finance.yahoo.com/healthcare/articles/siga-host-business-call-november-113000844.html). As of Oct 30, 2026, Yahoo Finance shows a market cap of ~$218.4M intraday, a prior close of $3.18, a 52-week range of $2.83–$8.46, TTM revenue of $53.66M, TTM net income of -$2.79M, total cash of $117.58M, and a "Bearish" Motley Fool rating [[22]](https://finance.yahoo.com/quote/SIGA/), [[23]](https://finance.yahoo.com/quote/SIGA/). (Note: the internal on-file market cap of ~$228.48M as of Oct 29 differs slightly from the intraday figure; the discrepancy likely reflects ordinary daily price movement.)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-siga-siga-technologies-inc-catalysts-narrative-risks-10402 (free to sign up)._